pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
363
stories
Aug 31, 26
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
Aug 31, 26
ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial
fiercebiotech
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 31, 26
STAT+: After a rough stretch, mRNA gets a boost — at least for now
stat
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 30, 26
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
stat
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 30, 26
#ESC26: AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial
endpoints
Aug 29, 26
STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
stat
Aug 28, 26
Juul gets OK to sell updated vaping device with age-gating technology
stat
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
biopharma dive
Aug 28, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 28, 26
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
stat
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
biospace
Aug 28, 26
STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
stat
Aug 28, 26
#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencer
endpoints
Aug 28, 26
Opinion: We quit the CDC last year. The problems we protested remain
stat
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
Aug 27, 26
A year on from Big Pharma’s pull-back from the UK, has anything changed?
fiercebiotech
Aug 27, 26
Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
endpoints
Aug 27, 26
What’s in Merck and Moderna’s cancer vaccine algorithm?
stat
Aug 27, 26
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
biospace
Aug 27, 26
STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
stat
Aug 27, 26
CEPI backs push to bring Egyptian biotech's Ebola vaccine into clinic to curb fast-growing outbreak
fiercebiotech
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
← prev
page 5 of 13
next →
